Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $12.00.

A partnership with fintech Apiture will give the bank new online and mobile banking services by the end of 2025.

RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) yesterday and set a price target of ...

AUSTIN, Texas--(BUSINESS WIRE)--Blue Sage Capital, a leading lower-middle market private equity firm, today announced the final close of Blue Sage Capital IV, L.P. (the “Fund”), at $618 ...

Sage's stock was up over 5% as of 10:30 a.m. Monday, and the company's market cap stood at $456 million While the board looks into options for Sage’s future, the company said it will be focused ...

The transaction reflects Sage’s strategy to manage its capital structure and potentially enhance shareholder value. More about Sage Group plc Sage Group plc is a UK-based company operating in ...

WILMINGTON, N.C.--(BUSINESS WIRE)--Apiture, a leading provider of digital banking solutions, today announced that Sage Capital Bank, an independent community financial institution serving ...

Blue Sage Capital, a leading lower-middle market private equity firm, today announced the final close of Blue Sage Capital IV ...